Rallybio CORP Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NASDAQ
Rallybio Corporation announces its anticipated merger closing date of November 20, 2026, alongside detailed procedures for a $13.90 per share cash distribution, including Nasdaq's due bill process.
NASDAQ
Rallybio Corporation is implementing a one-for-two reverse stock split, effective November 20, 2026, in preparation for its merger with Avenzo Therapeutics, Inc., after which it will be renamed Avenzo Therapeutics, Inc.
NASDAQ
Rallybio Corporation announced the postponement of its merger closing with Avenzo Therapeutics, Inc. due to unmet listing approval conditions.
NASDAQ
Martin Mackay, a Director of Rallybio Corp, reported multiple transactions in common stock on November 4, 2026.
NASDAQ
Ronald Hunt, a Director of Rallybio Corp, reported multiple transactions in common stock on November 4, 2026.
NASDAQ
Jonathan I Lieber, Chief Financial Officer of Rallybio Corp, reported multiple transactions in common stock on November 2, 2026.
NASDAQ
Jonathan I Lieber, Chief Financial Officer of Rallybio Corp, reported multiple transactions in common stock on October 29, 2026.
NASDAQ
Ronald Hunt, a Director of Rallybio Corp, reported multiple transactions in common stock on October 29, 2026.
NASDAQ
Christine A Nash, a Director of Rallybio Corp, reported multiple transactions in common stock on October 28, 2026.
NASDAQ
Stephen Uden, Chief Executive Officer and a Director of Rallybio Corp, reported multiple transactions in common stock on October 27, 2026.
NASDAQ
Jonathan I Lieber, Chief Financial Officer of Rallybio Corp, sold 599 shares of common stock on October 26, 2026 for $16.04 per share.
NASDAQ
Wendy Chung, a Director of Rallybio Corp, reported multiple transactions in common stock on October 26, 2026.
NASDAQ
Rallybio Corporation declared a special cash distribution of approximately $82.7 million, or an estimated $13.56 per share, in connection with its previously announced merger with Avenzo Therapeutics.
NASDAQ
Paula Soteropoulos, a Director of Rallybio Corp, reported multiple transactions in common stock on October 16, 2026.
NASDAQ
Helen M Boudreau, a Director of Rallybio Corp, reported multiple transactions in common stock on October 16, 2026.
NASDAQ
Robert Lorne Hopfner, a Director of Rallybio Corp, reported multiple transactions in common stock on October 12, 2026.
NASDAQ
Jonathan I Lieber, Chief Financial Officer of Rallybio Corp, reported multiple transactions in common stock on October 9, 2026.
NASDAQ
Stephen Uden, Chief Executive Officer and a Director of Rallybio Corp, reported multiple transactions in common stock on October 6, 2026.
NASDAQ
Jonathan I Lieber, Chief Financial Officer of Rallybio Corp, reported multiple transactions in common stock on September 29, 2026.
NASDAQ
Hui Liu, a Director of Rallybio Corp, reported multiple transactions in common stock on September 24, 2026.
NASDAQ
Wendy Chung, a Director of Rallybio Corp, reported multiple transactions in common stock on September 16, 2026.
NASDAQ
Rallybio Corporation announced a definitive agreement to acquire Avenzo Therapeutics, Inc., a clinical-stage oncology company, for an undisclosed sum, alongside a concurrent $215 million private placement financing.
NASDAQ
ADAR1 Capital Management, LLC reported the acquisition of 16,209 shares of Rallybio Corp common stock across multiple transactions.
NASDAQ
ADAR1 Capital Management, LLC reported the acquisition of 79,559 shares of Rallybio Corp common stock between May 13 and May 15, 2026.
NASDAQ
ADAR1 Capital Management, LLC and Daniel Schneeberger have increased their beneficial ownership in Rallybio Corp through recent open market purchases.
NASDAQ
ADAR1 Capital Management and Daniel Schneeberger acquired 155,905 shares of Rallybio Corp, signaling strong institutional confidence.
NASDAQ
Rallybio Corporation will acquire clinical-stage Candid Therapeutics in a merger, backed by over $505 million in new financing, to advance a T-cell engager pipeline for autoimmune diseases.
NASDAQ
Rallybio's Chief Financial Officer, Jonathan I Lieber, reported recent acquisitions and sales of company common stock, primarily for tax obligations.
NASDAQ
Rallybio Corporation's Director Martin Mackay was granted 18,055 stock options in lieu of $65,000 in retainer fees, vesting monthly through 2026.
NASDAQ
Rallybio Corp Director Ronald Hunt acquired 14,305 stock options with an exercise price of $4.45, vesting monthly through 2026.